Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
FluoroPharma Medical, Inc. (FPMI)
Montclair, NJ, US
FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of advanced molecular imaging agents. Initially, its efforts are concentrated on cardiovascular applications within the United States market. The company's pipeline features two notable product candidates: BFPET: An imaging agent designed for stress-testing patients with suspected or confirmed coronary artery disease (CAD), which has successfully completed its Phase I clinical trial. CardioPET: Another molecular imaging agent, currently undergoing a Phase IIa clinical trial. This compound aims to evaluate myocardial blood flow and metabolism in individuals afflicted with CAD. FluoroPharma Medical has established key collaborations, including licensing agreements with Massachusetts General Hospital and Sinotau USA. Furthermore, the company holds clinical research agreements with Pharmaceutical Product Development, LLC, and Cardiovascular Imaging Technologies. Established in 2003, FluoroPharma Medical, Inc. is headquartered in Montclair, New Jersey.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +100.00% | +0.00% | +100.00% | -50.00% | -96.08% | -99.91% | -99.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+44.5% ★ Q4'16: +90.8% (vs Q4'15)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'16: -6.3% (vs Q4'15)
-
Share dilution Biotechnology: -3.4%+11.7% Q4'16: +7.5% (vs Q4'15)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-7.83× Q4'16: -2.87× (vs Q4'15)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-01-07 | Spoor Johan M. | Director / Officer | A-Award | A | Common Stock Purchase Warrants | 10,000 | 0.83 | 8.3K | 10,000 | — | ↗ |
| 2012-11-26 | Spoor Johan M. | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.76 | 7.6K | 190,398 | — | ↗ |
| 2012-09-27 | Spoor Johan M. | Director / Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 180,398 | — | ↗ |
| 2012-09-12 | Spoor Johan M. | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 0.80 | 40.0K | 130,398 | — | ↗ |
| 2012-08-03 | Spoor Johan M. | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.84 | 4.2K | 80,398 | — | ↗ |
| 2012-06-15 | Spoor Johan M. | Director / Officer | P-Purchase | A | Common Stock | 6,000 | 0.82 | 4.9K | 75,398 | — | ↗ |
| 2011-11-18 | Spoor Johan M. | Officer | — | D | Common Stock | 0 | 0.00 | — | 69,398 | — | ↗ |
| 2011-05-17 | Spoor Johan M. | Officer | — | D | Warrants | 24,289 | 1.33 | 32.3K | 0 | — | ↗ |
| 2010-09-02 | Spoor Johan M. | Officer | — | D | Stock Options | 150,000 | 0.50 | 75.0K | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Edward L. Lyons Jr. | Vice President of Development | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FPMI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
